A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers

Nitin B. Charbe; Francisco Castillo; Murtaza M. Tambuwala; Parteek Prasher; Dinesh Kumar Chellappan; Aurora Carreño; Saurabh Satija; Sachin Kumar Singh; Monica Gulati; Kamal Dua; José Vicente González-aramundiz; Flavia C. Zacconi

doi:10.1016/j.blre.2022.100927

A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers

Nitin B. Charbe, Francisco Castillo, Murtaza M. Tambuwala, Parteek Prasher, Dinesh Kumar Chellappan, Aurora Carreño, Saurabh Satija, Sachin Kumar Singh, Monica Gulati, Kamal Dua, José Vicente González-aramundiz, Flavia C. Zacconi

Research output: Contribution to journal › Review article › peer-review

24 Citations (Scopus)

44 Downloads (Pure)

Abstract

Blood transfusion is the key to life in case of traumatic emergencies, surgeries and in several pathological conditions. An important goal of whole blood or red blood cell transfusion is the fast delivery of oxygen to vital organs and restoration of circulation volume. Whole blood or red blood cell transfusion has several limitations. Free haemoglobin not only loses its tetrameric configuration and extracts via the kidney leading to nephrotoxicity but also scavenges nitric oxide (NO), leading to vasoconstriction and hypertension. PFC based formulations transport oxygen in vivo, the contribution in terms of clinical outcome is challenging. The oxygen-carrying capacity is not the only criterion for the successful development of haemoglobin-based oxygen carriers (HBOCs). This review is a bird's eye view on the present state of the PFCs and HBOCs in which we analyzed the current modifications made or which are underway in development, their promises, and hurdles in clinical implementation.

Original language	English
Article number	100927
Pages (from-to)	1-102
Number of pages	102
Journal	Blood Reviews
Volume	54
Early online date	21 Jan 2022
DOIs	https://doi.org/10.1016/j.blre.2022.100927
Publication status	Published online - 21 Jan 2022

Bibliographical note

Funding Information:
This study was supported by ANID/CONICYT FONDECYT Postdoctorado Folio 3210316 from F.C. and ANID/CONICYT FO NDECYT Postdoctorado Folio 3180250 from N.B.C., Chile. A.C. thanks COLCIENCIAS (Ministerio de Ciencia Tecnología e Innovación - Colombia) for the fellowship No. 567/2012 to carry out Doctoral studies. The authors would like to thank Prof. M. Von Houssen L. for the English revision of this manuscript and Rolando Rebolledo M.D. for the medical revision. The figures and graphical abstract from this article were created with BioRender.com.

Funding Information:
This study was supported by ANID/CONICYT FONDECYT Postdoctorado Folio 3210316 from F.C. and ANID/CONICYT FONDECYT Postdoctorado Folio 3180250 from N.B.C., Chile. A.C. thanks COLCIENCIAS (Ministerio de Ciencia Tecnolog?a e Innovaci?n - Colombia) for the fellowship No. 567/2012 to carry out Doctoral studies. The authors would like to thank Prof. M. Von Houssen L. for the English revision of this manuscript and Rolando Rebolledo M.D. for the medical revision. The figures and graphical abstract from this article were created with BioRender.com.

Publisher Copyright:
© 2022

Keywords

Blood transfusion
Perfluorocarbons (PFCs)
Haemoglobin-based oxygen carriers (HBCOs)
Nitric oxide scavenging
Vasoconstriction
Recombinant haemoglobin
Haemoglobin-based oxygen carriers (HBOCs)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.blre.2022.100927

A new era in oxygen therapeuticsAuthor Accepted Manuscript, 116 KB

Cite this

Charbe, N. B., Castillo, F., Tambuwala, M. M., Prasher, P., Chellappan, D. K., Carreño, A., Satija, S., Singh, S. K., Gulati, M., Dua, K., González-aramundiz, J. V., & Zacconi, F. C. (2022). A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers. Blood Reviews, 54, 1-102. Article 100927. Advance online publication. https://doi.org/10.1016/j.blre.2022.100927

@article{c3aae8b7f0114531ab03d460cd7283d8,

title = "A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers",

abstract = "Blood transfusion is the key to life in case of traumatic emergencies, surgeries and in several pathological conditions. An important goal of whole blood or red blood cell transfusion is the fast delivery of oxygen to vital organs and restoration of circulation volume. Whole blood or red blood cell transfusion has several limitations. Free haemoglobin not only loses its tetrameric configuration and extracts via the kidney leading to nephrotoxicity but also scavenges nitric oxide (NO), leading to vasoconstriction and hypertension. PFC based formulations transport oxygen in vivo, the contribution in terms of clinical outcome is challenging. The oxygen-carrying capacity is not the only criterion for the successful development of haemoglobin-based oxygen carriers (HBOCs). This review is a bird's eye view on the present state of the PFCs and HBOCs in which we analyzed the current modifications made or which are underway in development, their promises, and hurdles in clinical implementation.",

keywords = "Blood transfusion, Perfluorocarbons (PFCs), Haemoglobin-based oxygen carriers (HBCOs), Nitric oxide scavenging, Vasoconstriction, Recombinant haemoglobin, Haemoglobin-based oxygen carriers (HBOCs)",

author = "Charbe, {Nitin B.} and Francisco Castillo and Tambuwala, {Murtaza M.} and Parteek Prasher and Chellappan, {Dinesh Kumar} and Aurora Carre{\~n}o and Saurabh Satija and Singh, {Sachin Kumar} and Monica Gulati and Kamal Dua and Gonz{\'a}lez-aramundiz, {Jos{\'e} Vicente} and Zacconi, {Flavia C.}",

note = "Funding Information: This study was supported by ANID/CONICYT FONDECYT Postdoctorado Folio 3210316 from F.C. and ANID/CONICYT FO NDECYT Postdoctorado Folio 3180250 from N.B.C., Chile. A.C. thanks COLCIENCIAS (Ministerio de Ciencia Tecnolog{\'i}a e Innovaci{\'o}n - Colombia) for the fellowship No. 567/2012 to carry out Doctoral studies. The authors would like to thank Prof. M. Von Houssen L. for the English revision of this manuscript and Rolando Rebolledo M.D. for the medical revision. The figures and graphical abstract from this article were created with BioRender.com. Funding Information: This study was supported by ANID/CONICYT FONDECYT Postdoctorado Folio 3210316 from F.C. and ANID/CONICYT FONDECYT Postdoctorado Folio 3180250 from N.B.C., Chile. A.C. thanks COLCIENCIAS (Ministerio de Ciencia Tecnolog?a e Innovaci?n - Colombia) for the fellowship No. 567/2012 to carry out Doctoral studies. The authors would like to thank Prof. M. Von Houssen L. for the English revision of this manuscript and Rolando Rebolledo M.D. for the medical revision. The figures and graphical abstract from this article were created with BioRender.com. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jan,

day = "21",

doi = "10.1016/j.blre.2022.100927",

language = "English",

volume = "54",

pages = "1--102",

journal = "Blood Reviews",

issn = "0268-960X",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers

AU - Charbe, Nitin B.

AU - Castillo, Francisco

AU - Tambuwala, Murtaza M.

AU - Prasher, Parteek

AU - Chellappan, Dinesh Kumar

AU - Carreño, Aurora

AU - Satija, Saurabh

AU - Singh, Sachin Kumar

AU - Gulati, Monica

AU - Dua, Kamal

AU - González-aramundiz, José Vicente

AU - Zacconi, Flavia C.

N1 - Funding Information: This study was supported by ANID/CONICYT FONDECYT Postdoctorado Folio 3210316 from F.C. and ANID/CONICYT FO NDECYT Postdoctorado Folio 3180250 from N.B.C., Chile. A.C. thanks COLCIENCIAS (Ministerio de Ciencia Tecnología e Innovación - Colombia) for the fellowship No. 567/2012 to carry out Doctoral studies. The authors would like to thank Prof. M. Von Houssen L. for the English revision of this manuscript and Rolando Rebolledo M.D. for the medical revision. The figures and graphical abstract from this article were created with BioRender.com. Funding Information: This study was supported by ANID/CONICYT FONDECYT Postdoctorado Folio 3210316 from F.C. and ANID/CONICYT FONDECYT Postdoctorado Folio 3180250 from N.B.C., Chile. A.C. thanks COLCIENCIAS (Ministerio de Ciencia Tecnolog?a e Innovaci?n - Colombia) for the fellowship No. 567/2012 to carry out Doctoral studies. The authors would like to thank Prof. M. Von Houssen L. for the English revision of this manuscript and Rolando Rebolledo M.D. for the medical revision. The figures and graphical abstract from this article were created with BioRender.com. Publisher Copyright: © 2022

PY - 2022/1/21

Y1 - 2022/1/21

N2 - Blood transfusion is the key to life in case of traumatic emergencies, surgeries and in several pathological conditions. An important goal of whole blood or red blood cell transfusion is the fast delivery of oxygen to vital organs and restoration of circulation volume. Whole blood or red blood cell transfusion has several limitations. Free haemoglobin not only loses its tetrameric configuration and extracts via the kidney leading to nephrotoxicity but also scavenges nitric oxide (NO), leading to vasoconstriction and hypertension. PFC based formulations transport oxygen in vivo, the contribution in terms of clinical outcome is challenging. The oxygen-carrying capacity is not the only criterion for the successful development of haemoglobin-based oxygen carriers (HBOCs). This review is a bird's eye view on the present state of the PFCs and HBOCs in which we analyzed the current modifications made or which are underway in development, their promises, and hurdles in clinical implementation.

AB - Blood transfusion is the key to life in case of traumatic emergencies, surgeries and in several pathological conditions. An important goal of whole blood or red blood cell transfusion is the fast delivery of oxygen to vital organs and restoration of circulation volume. Whole blood or red blood cell transfusion has several limitations. Free haemoglobin not only loses its tetrameric configuration and extracts via the kidney leading to nephrotoxicity but also scavenges nitric oxide (NO), leading to vasoconstriction and hypertension. PFC based formulations transport oxygen in vivo, the contribution in terms of clinical outcome is challenging. The oxygen-carrying capacity is not the only criterion for the successful development of haemoglobin-based oxygen carriers (HBOCs). This review is a bird's eye view on the present state of the PFCs and HBOCs in which we analyzed the current modifications made or which are underway in development, their promises, and hurdles in clinical implementation.

KW - Blood transfusion

KW - Perfluorocarbons (PFCs)

KW - Haemoglobin-based oxygen carriers (HBCOs)

KW - Nitric oxide scavenging

KW - Vasoconstriction

KW - Recombinant haemoglobin

KW - Haemoglobin-based oxygen carriers (HBOCs)

UR - https://linkinghub.elsevier.com/retrieve/pii/S0268960X22000017

UR - http://www.scopus.com/inward/record.url?scp=85123713657&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2022.100927

DO - 10.1016/j.blre.2022.100927

M3 - Review article

C2 - 35094845

SN - 0268-960X

VL - 54

SP - 1

EP - 102

JO - Blood Reviews

JF - Blood Reviews

M1 - 100927

ER -

A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this